Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.

Purpose: To describe indocyanine green angiography (ICGA) and visual acuity (VA) results in patients with neovascular age-related macular degeneration (nAMD) refractory to ranibizumab switched to aflibercept.

Methods: This study is a prospective interventional case series. Thirty-two eyes of 32 patients with nAMD showing a poor response after at least 24 months of ranibizumab were switched to aflibercept.

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization.

Purpose: To compare two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization.

Methods: A total of 61 eyes of 56 patients were treated: 26 eyes received a single injection followed by treatment pro re nata (1+ PRN), while 35 eyes first received 3 consecutive monthly injections (3+ PRN).

Results: The mean follow-up was 53 ± 16 months.

Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.

Purpose: To assess the effects of intravitreal ranibizumab therapy on intraocular pressure (IOP) and retinal nerve fiber (RNFL) thickness.

Methods: Forty-nine eyes of 49 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal ranibizumab injections and 27 fellow eyes not requiring treatment were followed for 1 year. RNFL thickness, as measured by Fourier domain optical coherence tomography, and IOP were determined pre- and postinjection.

Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.

Purpose: To evaluate the influence of retinal angiomatous proliferation (RAP) stage on visual and anatomic outcome after ranibizumab (Lucentis®).

Methods: This was a prospective study on consecutively diagnosed RAP eyes at the Hospital Clínico San Carlos, Madrid. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) are performed monthly.

Comparing corneal variables in healthy subjects and patients with primary open-angle glaucoma.

Purpose: This study was designed to identify possible differences between healthy subjects and patients with primary open-angle glaucoma (POAG) in keratometry, central corneal thickness, overall corneal thickness, mean thickness of a circular zone centered at the corneal apex of 1-mm radius (zone I), and mean thickness of several concentric rings also centered at the apex of 1-mm width (zones II to VI, respectively).

Methods: These variables were recorded in 126 healthy subjects and 130 patients with POAG. Corneal thicknesses and the power of the flattest and steepest axes were compared between the two populations using a t-test and the position of the flattest axis using a Mann-Whitney U test.

Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment.

Purpose: To identify predictive factors for visual outcome and need for retreatment after treating myopic choroidal neovascularization (CNV) with ranibizumab.

Design: A prospective interventional case series.

Methods: Sixty-seven eyes of 67 patients with myopic CNV were treated with 3 intravitreal ranibizumab injections given monthly.

Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.

Background: To report three cases of early choroidal neovascularization (CNV) bridging after ranibizumab treatment.

Methods: Three patients with two separated foci of CNV secondary to age-related macular degeneration (ARMD), pathologic myopia and multifocal choroiditis were treated with monthly injections of ranibizumab por a period of 3 months.

Results: All three cases showed early coalescence across the fovea of the two neovascular foci, already 1 month after the first ranibizumab injection.